References
- Maher ER, Neumann HP, Richard S. Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617–623. doi: 10.1038/ejhg.2010.175.
- Weil RJ, Lonser RR, DeVroom HL, et al. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):95–105. doi: 10.3171/jns.2003.98.1.0095.
- Lonser RR, Butman JA, Huntoon K, et al. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg. 2014;120(5):1055–1062. doi: 10.3171/2014.1.JNS131431.
- Dollfus H, Massin P, Taupin P, et al. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci. 2002;43:3067–3074.
- Varshney N, Kebede AA, Owusu-Dapaah H, et al. A review of von Hippel-Lindau syndrome. J Kidney Cancer VHL. 2017;4(3):20–29. doi: 10.15586/jkcvhl.2017.88.
- Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990;77(283):1151–1163. doi: 10.1093/qjmed/77.2.1151.
- Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55–64. doi: 10.1038/nrc3844.
- Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31(5):521–537. doi: 10.1002/humu.21219.
- Kaelin WG.Jr., Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2(9):673–682. doi: 10.1038/nrc885.
- Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 1998;12(6):417–423. doi: 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.3.CO;2-B.
- Peng S, Shepard M, Wang J, et al. Genotype-phenotype correlations in chinese von Hippel-Lindau disease patients. Oncotarget. 2017;8(24):38456–38465. doi: 10.18632/oncotarget.16594.
- Stebbins CE, Kaelin WG, Jr., Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999;284(5413):455–461. doi: 10.1126/science.284.5413.455.
- Melmon K, Rosen S. Lindau’s disease. Review of the literature and study of a large kindred. Am J Med. 1964;36(4):595–617. doi: 10.1016/0002-9343(64)90107-x.
- He ZW, Xia L, Deng ZY, et al. Identification of a VHL gene mutation in a Chinese family with von Hippel-Lindau syndrome. Mol Med Rep. 2018;18:435–440.
- Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2(7):423–427. doi: 10.1038/35017054.
- Jh M, H Y, M I, et al. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science. 2002;296:1886–1889.
- Bailly M, Bain C, Favrot MC, et al. Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers. Int J Cancer. 1995;63(5):660–664. doi: 10.1002/ijc.2910630510.
- Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85–90. doi: 10.1038/ng0594-85.
- Maher ER, Webster AR, Richards FM, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996;33(4):328–332. doi: 10.1136/jmg.33.4.328.
- Barry RE, Krek W. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med. 2004;10(9):466–472. doi: 10.1016/j.molmed.2004.07.008.
- Cybulski C, Krzystolik K, Murgia A, et al. Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet. 2002;39(7):E38–38. doi: 10.1136/jmg.39.7.e38.
- Franke G, Bausch B, Hoffmann MM, et al. Alu-Alu recombination underlies the vast majority of large VHL germline deletions: molecular characterization and genotype-phenotype correlations in VHL patients. Hum Mutat. 2009;30(5):776–786. doi: 10.1002/humu.20948.